» Articles » PMID: 37098542

MicroRNAs As the Critical Regulators of Autophagy-mediated Cisplatin Response in Tumor Cells

Overview
Journal Cancer Cell Int
Publisher Biomed Central
Date 2023 Apr 25
PMID 37098542
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy is one of the most common therapeutic methods in advanced and metastatic tumors. Cisplatin (CDDP) is considered as one of the main first-line chemotherapy drugs in solid tumors. However, there is a high rate of CDDP resistance in cancer patients. Multi-drug resistance (MDR) as one of the main therapeutic challenges in cancer patients is associated with various cellular processes such as drug efflux, DNA repair, and autophagy. Autophagy is a cellular mechanism that protects the tumor cells toward the chemotherapeutic drugs. Therefore, autophagy regulatory factors can increase or decrease the chemotherapy response in tumor cells. MicroRNAs (miRNAs) have a pivotal role in regulation of autophagy in normal and tumor cells. Therefore, in the present review, we discussed the role of miRNAs in CDDP response through the regulation of autophagy. It has been reported that miRNAs mainly increased the CDDP sensitivity in tumor cells by inhibition of autophagy. PI3K/AKT signaling pathway and autophagy-related genes (ATGs) were the main targets of miRNAs in the regulation of autophagy-mediated CDDP response in tumor cells. This review can be an effective step to introduce the miRNAs as efficient therapeutic options to increase autophagy-mediated CDDP sensitivity in tumor cells.

Citing Articles

Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells.

Maharati A, Rajabloo Y, Moghbeli M Heliyon. 2025; 11(1):e41483.

PMID: 39834411 PMC: 11743095. DOI: 10.1016/j.heliyon.2024.e41483.


Diagnostic Value of Plasma Long Non-coding SLC26A4 Antisense RNA 1 Combined with Magnetic Resonance Imaging in Rectal Cancer.

Li Z, Pu M, Zhou P, Zhang T, Xu Y, Zhang Y Turk J Gastroenterol. 2024; 35(12):900-908.

PMID: 39641247 PMC: 11639608. DOI: 10.5152/tjg.2024.23558.


MicroRNA-98 as a novel diagnostic marker and therapeutic target in cancer patients.

Akhlaghipour I, Moghbeli M Discov Oncol. 2024; 15(1):385.

PMID: 39210158 PMC: 11362465. DOI: 10.1007/s12672-024-01270-z.


Exploring the nexus between MYH9 and tumors: novel insights and new therapeutic opportunities.

Gou Z, Zhang D, Cao H, Li Y, Li Y, Zhao Z Front Cell Dev Biol. 2024; 12:1421763.

PMID: 39149512 PMC: 11325155. DOI: 10.3389/fcell.2024.1421763.


MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma.

Palizkaran Yazdi M, Barjasteh A, Moghbeli M Mol Brain. 2024; 17(1):42.

PMID: 38956588 PMC: 11218189. DOI: 10.1186/s13041-024-01113-6.


References
1.
Ferrari S, Serra M . An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 2015; 16(18):2727-36. DOI: 10.1517/14656566.2015.1102226. View

2.
Hao Y, Li J, Zhang H, Guan G, Guo Y . MicroRNA-205 targets HER3 and suppresses the growth, chemosensitivity and metastasis of human nasopharyngeal carcinoma cells. J BUON. 2020; 25(1):350-356. View

3.
Kikuchi K, Soundararajan A, Zarzabal L, Weems C, Nelon L, Hampton S . Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2012; 32(3):286-95. PMC: 3360112. DOI: 10.1038/onc.2012.46. View

4.
Fu J, Cai H, Wu Y, Fang S, Wang D . Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Gene. 2020; 755:144886. DOI: 10.1016/j.gene.2020.144886. View

5.
He J, Yu J, Xu Q, Wang L, Zheng J, Liu L . Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy. 2015; 11(2):373-84. PMC: 4502709. DOI: 10.1080/15548627.2015.1009781. View